Tau Biomarkers in Late-onset Psychosis (LOP)

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

Hallucinations or delusions that occur for the first time in older people with no acute medical problems or mood symptoms may be related to impending dementia. This study aims to confirm this hypothesis using novel blood biomarkers and Positron Emission Tomography (PET) imaging tracers, as well as non-invasive testing.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 65
Maximum Age: 85
View:

• Male or female, aged 65-85 years.

• Diagnosis of late-onset non-affective primary psychotic disorder consistent with either very late-onset schizophrenia-like psychosis (VLOSP, International Late-Onset Schizophrenia Group consensus criteria, Howard et al., 2000) or delusional disorder (DSM-5 criteria)

• Caregiver available to provide collateral history and participation in informant-based ratings (NPI,CDR)

• Clinical Dementia Rating (CDR) score of 0 or 0.5.

• Mini-Mental State Examination (MMSE) score ≥ 24 and at the screening visit.

• Normal memory function (to rule-out mild cognitive impairment, MCI) documented by scoring within 1.5 SD range in education adjusted norms of the Logical Memory II subscale

• Ability to hear 500, 1000 and 1500 Hz bilaterally on a hearing evaluation (hearing aids permitted).

Locations
United States
New York
The Feinstein Institutes for Medical Research
RECRUITING
Manhasset
Contact Information
Primary
Nichole Hoehn, MS
nhoehn@northwell.edu
516-562-3492
Backup
Erica Christen, MS
EChriste@northwell.edu
516-562-3492
Time Frame
Start Date: 2024-02-16
Estimated Completion Date: 2027-06-30
Participants
Target number of participants: 16
Related Therapeutic Areas
Sponsors
Leads: Jeremy Koppel
Collaborators: National Institute of Mental Health (NIMH)

This content was sourced from clinicaltrials.gov

Similar Clinical Trials